Search Results

7 results

  1. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 58

    A consortium approach for consumer-reported outcome measures to assess tobacco- and nicotine-containing products

    ACQUADRO C.(1) on behalf of the CORESTA CROM Task Force: AYALA-FIERRO F.(2); BLACK R.(3); CAHOURS X.(4); CHREA C.(5); CURTIN G.(6); GILES L.(7); McCAFFREY S.(3); PARK C.H.(8); PRASAD K.(9); SHERWOOD N.(10); SHIFFMAN S.(11); SMITH J.(6); SPIES E.(5)
    (1) Mapi Research Trust, Lyon, France; (2) ITG Brands, Greensboro, NC, U.S.A.; (3) Altria Client Services, Richmond, VA, U.S.A.; (4) SEITA - Imperial Brands, Paris, France; (5) Philip Morris Products S.A., Neûchatel, Switzerland; (6) RAIS, Winston-Salem, NC, U.S.A.; (7) JT Int'l SA, Genève, Switzerland; (8) KT&G Research Institute, Daejeon, Republic of Korea; (9) British American Tobacco, Southampton, U.K.; (10) Neil Sherwood Consulting, Commugny, Switzerland; (11) Pinney Associates, Pittsburgh, PA, U.S.A.
    In the tobacco space, consumer-reported outcome measures (CROM) are essential for understanding motivations, subjective effects, and behavior. Such measures have become particularly important with the advent of candidate modified risk tobacco...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STW 08

    Modeling the impact of a tobacco product with a modified risk claim on population health: the role of sensitivity analyses

    MUHAMMAD-KAH R.; PITHAWALLA Y.B.; BLACK R.; WEI L.; HANNEL T.; SARKAR M.
    Altria Client Services LLC, Richmond, VA 23219, U.S.A.
    Computational models can be used to assess the population health impact of a modified risk claim on a tobacco product, while taking into account tobacco users and non-tobacco users. We present here a case study of a smokeless tobacco (ST) product...
  3. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 37

    Assessing the population health impact of authorizing the marketing of a smokeless tobacco product with a proposed modified risk claim

    MUHAMMAD-KAH R.(1); PITHAWALLA Y.B.(1); JONES M.(1); WEI L.(1); BRYAN T.(1); BLACK R.(1); BOONE E.(2); SARKAR M.(1)
    (1) Altria Client Services LLC, Richmond, VA, U.S.A.; (2) Virginia Commonwealth University, Richmond, VA, U.S.A.
    Computational models can be used to predict population effects following the market authorization of a tobacco product with a modified risk claim. Using best modeling practices we developed and validated a population model. Since moist smokeless...
  4. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 05

    Examining intra-individual and inter-individual variability of plasma nicotine PK parameters in e-vapor use by adult cigarette smokers in three studies

    LIANG Qiwei; ZHAO Yuxi; WANG Jingzhu; BLACK R.
    Altria Client Services LLC, Center for Research and Technology, Richmond, VA, U.S.A.
    Pharmacokinetic studies are often used to assess the rate and amount of nicotine delivery into the bloodstream during product use. Knowledge about intra-individual and inter-individual variability of pharmacokinetic (PK) parameters is important in...
  5. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 31

    The relationship between pharmacokinetic parameters and the amount of e-liquid used by cigarette smokers under two e-vapor product use conditions

    LIANG Qiwei; WANG Jingzhu; BLACK R.; LIU Jianmin
    Altria Client Services LLC, Center for Research and Technology, Richmond, VA, U.S.A.
    Plasma nicotine pharmacokinetic (PK) parameters have been used for assessing the rate and amount of nicotine uptake from use of e-vapor products (EVPs). The purpose of this study is to examine the relationship between each of the two PK parameters,...
  6. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 57

    Assessing the potential population health impact of market authorization of e-cigarettes in the U.S.

    MUHAMMAD-KAH R.; PITHAWALLA Y.B.; HANNEL T.; WEI L.; BLACK R.; BRYAN T.; GOGOVA M.
    Altria Client Services LLC, Richmond, VA, U.S.A.
    When evaluating a Premarket Tobacco Product Application (PMTA) or Modified Risk Tobacco Product Application (MRTPA), the Food and Drug Administration (FDA) employs a Population Health Standard, which requires evaluation of risk and benefit to the...
  7. TSRC, Tob. Sci. Res. Conf., 2018, 72, abstr. 099a & 99b

    Machine made cigar leaf and product workshop

    STEVENS R.(1); BLACK R.(1); GILLMAN I.G.(2); SMITH J.(3); HARTLEY M.(4); LINDEGAARD T.(5)
    (1) ITG Brands LLC, Greensboro, NC, USA; (2) Enthalpy Labs, Durham, NC, USA; (3) Altria Client Services LLC, Richmond, VA, USA; (4) Universal Dark Air-Cured Group, Oxford, NC, USA
    The regulation of tobacco products continues to be a growing focus around the world. For example, in 2016, the FDA finalized a rule in the USA that extended its regulatory authority to all tobacco products, including e-cigarettes, cigars, hookah, and...